Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells

Lena Kastl, Iain Brown, Andrew C Schofield

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

To quantify gene expression levels, appropriate controls have to be used to adjust for experimental variation. Endogenous control genes are widely used as they are stably expressed independent of cell cycle and experimental conditions, however, they can be altered upon drug treatment. DNA methylation is widely studied in chemotherapy drug resistance and the DNA methylation inhibitor decitabine showed promising results reversing drug resistance in cancer. We aimed to investigate the effect of different decitabine concentrations on the expression of selected endogenous control genes (GAPDH, 18S rRNA, PPIA, RPL13A, OAZ1) in two docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) compared to untreated cells. In MCF-7 cells, 18S rRNA remained stable, however, GAPDH, PPIA and OAZ1 gene expression was increased after treatment. RPL13A was stably expressed at 8 µM decitabine but was increased at lower drug concentrations. In MDA-MB-231 cells, GAPDH levels remained relatively stable following decitabine treatment and so was PPIA expression at low decitabine concentrations. Decitabine increased 18S rRNA, RPL13A and OAZ1 gene expression. In this study, we observed cell line specific effects of decitabine and suggest that 18S rRNA is most suitable to use in MCF-7 cells, while GAPDH is recommended to use in MDA-MB-231 cells during decitabine treatment.
Original languageEnglish
Pages (from-to)87-92
Number of pages6
JournalMolecular and Cellular Probes
Volume24
Issue number2
Early online date16 Oct 2009
DOIs
Publication statusPublished - Apr 2010

Fingerprint

decitabine
Breast Neoplasms
Genes
MCF-7 Cells
docetaxel
DNA Methylation
Gene Expression
Drug Resistance
Cell Line
Therapeutics
Pharmaceutical Preparations

Keywords

  • breast cancer cells
  • decitabine
  • DNA methylation
  • endogenous control genes
  • normalisation

Cite this

Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells. / Kastl, Lena; Brown, Iain; Schofield, Andrew C.

In: Molecular and Cellular Probes, Vol. 24, No. 2, 04.2010, p. 87-92.

Research output: Contribution to journalArticle

Kastl, Lena ; Brown, Iain ; Schofield, Andrew C. / Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells. In: Molecular and Cellular Probes. 2010 ; Vol. 24, No. 2. pp. 87-92.
@article{cdeef3f88b56464384893e7c420e2a87,
title = "Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells",
abstract = "To quantify gene expression levels, appropriate controls have to be used to adjust for experimental variation. Endogenous control genes are widely used as they are stably expressed independent of cell cycle and experimental conditions, however, they can be altered upon drug treatment. DNA methylation is widely studied in chemotherapy drug resistance and the DNA methylation inhibitor decitabine showed promising results reversing drug resistance in cancer. We aimed to investigate the effect of different decitabine concentrations on the expression of selected endogenous control genes (GAPDH, 18S rRNA, PPIA, RPL13A, OAZ1) in two docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) compared to untreated cells. In MCF-7 cells, 18S rRNA remained stable, however, GAPDH, PPIA and OAZ1 gene expression was increased after treatment. RPL13A was stably expressed at 8 µM decitabine but was increased at lower drug concentrations. In MDA-MB-231 cells, GAPDH levels remained relatively stable following decitabine treatment and so was PPIA expression at low decitabine concentrations. Decitabine increased 18S rRNA, RPL13A and OAZ1 gene expression. In this study, we observed cell line specific effects of decitabine and suggest that 18S rRNA is most suitable to use in MCF-7 cells, while GAPDH is recommended to use in MDA-MB-231 cells during decitabine treatment.",
keywords = "breast cancer cells, decitabine, DNA methylation, endogenous control genes, normalisation",
author = "Lena Kastl and Iain Brown and Schofield, {Andrew C}",
year = "2010",
month = "4",
doi = "10.1016/j.mcp.2009.10.007",
language = "English",
volume = "24",
pages = "87--92",
journal = "Molecular and Cellular Probes",
issn = "0890-8508",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells

AU - Kastl, Lena

AU - Brown, Iain

AU - Schofield, Andrew C

PY - 2010/4

Y1 - 2010/4

N2 - To quantify gene expression levels, appropriate controls have to be used to adjust for experimental variation. Endogenous control genes are widely used as they are stably expressed independent of cell cycle and experimental conditions, however, they can be altered upon drug treatment. DNA methylation is widely studied in chemotherapy drug resistance and the DNA methylation inhibitor decitabine showed promising results reversing drug resistance in cancer. We aimed to investigate the effect of different decitabine concentrations on the expression of selected endogenous control genes (GAPDH, 18S rRNA, PPIA, RPL13A, OAZ1) in two docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) compared to untreated cells. In MCF-7 cells, 18S rRNA remained stable, however, GAPDH, PPIA and OAZ1 gene expression was increased after treatment. RPL13A was stably expressed at 8 µM decitabine but was increased at lower drug concentrations. In MDA-MB-231 cells, GAPDH levels remained relatively stable following decitabine treatment and so was PPIA expression at low decitabine concentrations. Decitabine increased 18S rRNA, RPL13A and OAZ1 gene expression. In this study, we observed cell line specific effects of decitabine and suggest that 18S rRNA is most suitable to use in MCF-7 cells, while GAPDH is recommended to use in MDA-MB-231 cells during decitabine treatment.

AB - To quantify gene expression levels, appropriate controls have to be used to adjust for experimental variation. Endogenous control genes are widely used as they are stably expressed independent of cell cycle and experimental conditions, however, they can be altered upon drug treatment. DNA methylation is widely studied in chemotherapy drug resistance and the DNA methylation inhibitor decitabine showed promising results reversing drug resistance in cancer. We aimed to investigate the effect of different decitabine concentrations on the expression of selected endogenous control genes (GAPDH, 18S rRNA, PPIA, RPL13A, OAZ1) in two docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) compared to untreated cells. In MCF-7 cells, 18S rRNA remained stable, however, GAPDH, PPIA and OAZ1 gene expression was increased after treatment. RPL13A was stably expressed at 8 µM decitabine but was increased at lower drug concentrations. In MDA-MB-231 cells, GAPDH levels remained relatively stable following decitabine treatment and so was PPIA expression at low decitabine concentrations. Decitabine increased 18S rRNA, RPL13A and OAZ1 gene expression. In this study, we observed cell line specific effects of decitabine and suggest that 18S rRNA is most suitable to use in MCF-7 cells, while GAPDH is recommended to use in MDA-MB-231 cells during decitabine treatment.

KW - breast cancer cells

KW - decitabine

KW - DNA methylation

KW - endogenous control genes

KW - normalisation

U2 - 10.1016/j.mcp.2009.10.007

DO - 10.1016/j.mcp.2009.10.007

M3 - Article

VL - 24

SP - 87

EP - 92

JO - Molecular and Cellular Probes

JF - Molecular and Cellular Probes

SN - 0890-8508

IS - 2

ER -